

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Zai Lab Limited

再鼎醫藥有限公司*

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 9688)

NOTICE OF BOARD ACTION AND DATE OF PUBLICATION OF 2023 ANNUAL RESULTS ANNOUNCEMENT

Zai Lab Limited (the “**Company**”) hereby announces that the board of directors of the Company (the “**Board**”) will, on February 27, 2024 (Tuesday, U.S. Eastern Time)/ February 28, 2024 (Wednesday, Shanghai and Hong Kong Time), consider and approve, among other matters, the financial results of the Company and its subsidiaries for the year ended December 31, 2023 (the “**Annual Results**”), which are prepared in accordance with U.S. Generally Accepted Accounting Principles (“**U.S. GAAP**”) and the applicable rules of the U.S. Securities and Exchange Commission (the “**SEC**”), and the publication thereof.

If the Annual Results are approved by the Board, the Company will publish an announcement on the Annual Results on February 27, 2024 (Tuesday, U.S. Eastern Time)/ February 28, 2024 (Wednesday, Shanghai and Hong Kong Time) on the website of The Stock Exchange of Hong Kong Limited at www.hkexnews.hk and the website of the Company at <http://ir.zailaboratory.com>.

After the Annual Results have been approved and released, the management of the Company plans to host a live earnings teleconference call and webcast at 8:00 a.m. on February 28, 2024 (Wednesday, U.S. Eastern Time) / 9:00 p.m. on February 28, 2024 (Wednesday, Shanghai and Hong Kong Time) to discuss the Annual Results and answer questions. Interested parties may access the live webcast via the Company’s website at <http://ir.zailaboratory.com>. All participants must use the link provided below to complete the online registration process in advance of the conference call. Dial-in details will be provided in the confirmation email which the participants will receive after registration.

Registration link:

<https://register.vevent.com/register/BIa1fd72e50c9e4117b696c49bdfa9f83b>

A replay of the conference call will be made available shortly after the end of the call at the Company’s website at <http://ir.zailaboratory.com>.

The Company will further issue an announcement of its annual results for the fiscal year ended December 31, 2023 in accordance with the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**HK Listing Rules**”) on or before March

31, 2024, which are expected to be the same as the Annual Results prepared in accordance with the U.S. GAAP and the applicable rules of the SEC, except for specific additional information required by the HK Listing Rules, together with a reconciliation of the Annual Results from U.S. GAAP to International Financial Reporting Standards.

By order of the Board

Zai Lab Limited

Samantha Du

Director, Chairperson and Chief Executive Officer

Hong Kong, February 16, 2024

As at the date of this announcement, the board of directors of the Company comprises Dr. Samantha Du as a director, and Dr. Kai-Xian Chen, Dr. John Diekman, Richard Gaynor, M.D., Ms. Nisa Leung, Mr. William Lis, Mr. Scott W. Morrison, Mr. Leon O. Moulder, Jr., Mr. Michel Vounatsos and Mr. Peter Wirth as independent directors.

** For identification only*